Regal Assets Analytics

SanaCurrents Updates

Agile’s Twirla FDA Approval Helps Shares

By |2020-03-30T10:11:59-04:00February 19th, 2020|Categories: Bill Langbein, Healthcare, Pharmaceutical & Biotechnology, SanaCurrents, SanaCurrents Updates|

Agile Therapeutics, Inc. (NASDAQ:AGRX) announced FDA approval of its contraceptive [...]

Bioxcel Rockets After Suntrust Upgrade; Agile Volatile Ahead Of FDA Decision

By |2020-03-30T10:12:21-04:00February 14th, 2020|Categories: Bill Langbein, Healthcare, Pharmaceutical & Biotechnology, SanaCurrents, SanaCurrents Updates|Tags: , |

BioXcel Therapeutics (NASDAQ:BTAI) soared this morning to about $38 per [...]

vTv Therapeutics (VTVT) Nearly Doubles in Monday trading after positive phase II data

By |2020-03-30T10:12:35-04:00February 10th, 2020|Categories: Bill Langbein, Healthcare, Pharmaceutical & Biotechnology, SanaCurrents, SanaCurrents Updates|Tags: |

Shares of vTv Therapeutics (NASDAQ:VTVT) soared Monday morning, briefly eclipsing [...]

Twist Turns Higher after Settlement with Agilent

By |2020-02-14T12:44:18-05:00February 7th, 2020|Categories: Bill Langbein, Healthcare, Pharmaceutical & Biotechnology, SanaCurrents, SanaCurrents Updates|Tags: |

Twist Bioscience Corporation (NASDAQ:TWST) moved higher in the last 24 [...]

Acceleron Soars, Another Catalyst on the Way, And a Few Changes to Your SanaCurrents Home page

By |2020-02-15T11:38:23-05:00January 31st, 2020|Categories: Bill Langbein, Healthcare, Pharmaceutical & Biotechnology, SanaCurrents, SanaCurrents Updates|

Acceleron Soars Shares of Acceleron Pharma (NASDAQ: XLRN) climbed nearly [...]

[SanaCurrents Update] – Promising Phase I Data Help Denali (DNLI) Shares

By |2020-02-15T11:40:21-05:00January 16th, 2020|Categories: Healthcare, Pharmaceutical & Biotechnology, SanaCurrents, SanaCurrents Probability Sentiment, SanaCurrents Updates|

Shares of Denali Therapeutics (NASDAQ: DNLI) pulled back slightly on [...]

Blueprint Gains Approval for Cancer Drug, Shares Climbing

By |2020-02-15T11:41:35-05:00January 10th, 2020|Categories: Bill Langbein, Health Care Equipment & Services, Healthcare, In Depth Research, SanaCurrents, SanaCurrents Updates|

The FDA approved the lead cancer drug from Blueprint Medicines [...]